Posts

• Al Jazeera
• BBC World Service
• Bloomberg
• Bloomberg
• Bloomberg
• Bloomberg and Businessweek feature CN Bio Innovations’ LiverChip Platform
• Cell4Pharma agreement
• Changing Times, Why Pharmacokinetics Matter in Drug Discovery
• CN Bio and Cambridge University identify novel regulatory pathway driving NASH
• CN Bio and iiCON announce COVID-19 research collaboration
• CN Bio and Imperial College London Collaboration
• CN Bio and MIT announce 10 Organ-On-Chip Platform: Nature Scientific Reports
• CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
• CN Bio announces opening of new Biosafety Level 3 facility
• CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals
• CN Bio announces research collaboration with gene silencing specialist Benitec Biopharma
• CN Bio appoints Dr David Hughes to board of directors
• CN Bio appoints Emma Sceats as CEO
• CN Bio appoints Professor Mark Thursz as Scientific Advisor
• CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
• CN Bio expands service offering to support oncology drug discovery
• CN Bio FDA collaboration expanded
• CN Bio featured on the Discovery Channel
• CN Bio hires Director of Licensing
• CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014
• CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist
• CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company
• CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University
• CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb
• CN Bio Innovations announces LiverChip research study with leading pharmaceutical company
• CN Bio Innovations announces research collaboration with Alnylam
• CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies
• CN Bio Innovations features in Al Jazeera documentary “The Cure”
• CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London
• CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
• CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
• CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
• CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
• CN Bio makes key senior appointments to support international commercial development
• CN Bio MicroMix to be featured at AACR
• CN Bio Sponsors the Organ-On-Chip world congress in Boston
• CN Bio to bring 10 organs together on a chip
• CN Bio to provide drug metabolism and safety toxicity testing services
• CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
• CN Bio’s PhysioMimix™ technology receives FDA recognition
• De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
• Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award
• FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation
• Flowing to the Beat of Your Heart
• Hepatitis B research using CN Bio Organ-on-Chips published in Nature Communications
• How a novel <em>in vitro</em> Liver-on-a-Chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
• Huffington Post features CN Bio
• Imperial College London to present first public HBV data from CN Bio in vitro liver model
• Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting
• Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease
• Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System
• Life in the Fastlane
• Liver disease to become a bigger killer than heart disease or cancer
• Lonza and CN Bio Announce Distribution Agreement
• MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress
• NAFLD vs MAFLD: could a name change impact the progression of liver disease research?
• NASH Drug Discovery Service Launched at AASLD
• NIH Director highlights LiverChip in Compton Lecture
• Of Mice and Men – Will human organ-on-a-chip disease models replace animal use?
• Organ-on-Chip Webinar: Improving Preclinical Studies for Faster Drug Development
• PharmaVentures Interview: Will Organ-on-Chip technology provide the data Regulators need in the future?
• PhysioMimix™ Human 3D Cell Culture wins Lab Innovation 2018 Award
• PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021'
• Promotion of Dr David Hughes to the role of Chief Technology Officer
• R&D 100 Award won by Vanderbilt team for tech being developed with CN Bio
• Radio 4’s PM features CN Bio Human Organ-on-Chips
• Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
• The Economist
• TSB Funds New Research by CN Bio into Fatty Liver Disease
• Zyoxel Ltd to become CN Bio Innovations Ltd